Traumatic brain injury (TBI) is a global health problem, for which there are no approved therapies. Advances in acute clinical care have improved post-TBI survival, yet many patients are left with chronic TBI-related disabilities (i.e. chronic TBI). Existing treatments that focus on rehabilitation and symptom management do not modify the disease and have limited effectiveness. Consequently, chronic TBI-related disabilities remain a significant unmet medical need. Cell therapies have neuroprotective and neurorestorative effects which are believed to modify the disease. In this article, we review the safety and efficacy of cell therapies in early-phase clinical studies that have shown potential to improve outcomes in acute to chronic phases of TBI.
CITATION STYLE
Kawabori, M., Chida, D., Nejadnik, B., Stonehouse, A. H., & Okonkwo, D. O. (2022). Cell therapies for acute and chronic traumatic brain injury. Current Medical Research and Opinion. Taylor and Francis Ltd. https://doi.org/10.1080/03007995.2022.2141482
Mendeley helps you to discover research relevant for your work.